Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model

Drishya Kurup, Delphine C. Malherbe, Christoph Wirblich, Rachael Lambert, Adam J. Ronk, Leila Zabihi Diba, Alexander Bukreyev, Matthias J. Schnell

    Research output: Contribution to journalArticlepeer-review

    14 Scopus citations

    Abstract

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emergent coronavirus that has caused a worldwide pandemic. Although human disease is often asymptomatic, some develop severe illnesses such as pneumonia, respiratory failure, and death. There is an urgent need for a vaccine to prevent its rapid spread as asymptomatic infections accounting for up to 40% of transmission events. Here we further evaluated an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model. CORAVAX adjuvanted with MPLA-AddaVax, a TRL4 agonist, induced high levels of neutralizing antibodies and generated a strong Th1-biased immune response. Vaccinated hamsters were protected from weight loss and viral replication in the lungs and nasal turbinates three days after challenge with SARS-CoV-2. CORAVAX also prevented lung disease, as indicated by the significant reduction in lung pathology. This study highlights CORAVAX as a safe, immunogenic, and efficacious vaccine that warrants further assessment in human trials.

    Original languageEnglish (US)
    Article numbere1009383
    JournalPLoS pathogens
    Volume17
    Issue number3
    DOIs
    StatePublished - Mar 2021

    ASJC Scopus subject areas

    • Parasitology
    • Microbiology
    • Immunology
    • Molecular Biology
    • Genetics
    • Virology

    Fingerprint

    Dive into the research topics of 'Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model'. Together they form a unique fingerprint.

    Cite this